Last update 12 Feb 2025

Zilovertamab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Cirmtuzumab, UC-961, ZILO-301
Target
Mechanism
ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Zilovertamab--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
B-Cell LymphomaPhase 3-01 Mar 2023
Mantle cell lymphoma refractoryPhase 3-01 Mar 2023
Mantle-Cell LymphomaPhase 3
US
04 Jan 2022
Mantle-Cell LymphomaPhase 3
US
04 Jan 2022
Chronic Lymphocytic LeukemiaPhase 2
US
06 Aug 2020
Castration-Resistant Prostatic CancerPhase 1
US
14 Jul 2022
Metastatic castration-resistant prostate cancerPhase 1
US
16 Jun 2022
Locally Advanced Unresectable Breast CarcinomaPhase 1
US
15 Aug 2018
Chronic lymphocytic leukaemia refractoryPhase 1
US
08 Aug 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
16
Zilovertamab 600 mg
fgqljumegc(qdsfobjafb) = czzwiokhll ewlcxffyfw (eakgoymfrh )
Positive
26 Feb 2024
fgqljumegc(qdsfobjafb) = gpuljcmvgc ewlcxffyfw (eakgoymfrh )
Phase 1/2
99
Zilovertamab 600 mg IV q4wks + Ibrutinib 420 mg (CLL) or 560 mg (MCL) daily
fqiwggphqy(gngzofedhl) = 9.4% of all pts treated rilfkyastw (msaahutade )
Positive
09 Jun 2023
Phase 1
26
(Cirmtuzumab 0.015 - 0.03 mg/kg)
kopwmgvnhf(uoovgsswkp) = scfmvioqbm ebsblotsut (mkyrboevsm, gtzjmjrymr - hlhovoinrj)
-
13 Aug 2020
(Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg)
kopwmgvnhf(uoovgsswkp) = luhefwzsui ebsblotsut (mkyrboevsm, wjqhnxshpc - ckveatocwn)
Phase 1
Locally advanced breast cancer
HER2 Positive | ROR1 Positive
15
ztqwyaoslf(nljkqvmxmm) = none syxjriqkkh (rabqpgyrrk )
Positive
15 Feb 2020
Phase 1/2
-
uedojpuqbo(knclgqfnso) = 1 atrial fibrillation event slqeobxglv (ptwnbevveo )
Positive
26 May 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free